文献速递治疗药物监测与药物基因组学特殊人群用药药物不良反应与药物警戒

治疗药物监测指导阿尔茨海默病中利培酮的安全处方

Guiding safer risperidone prescribing in Alzheimer's disease with therapeutic drug monitoring.
PubMed 文献 · Br J Clin Pharmacol · 2023-02-28

本研究基于痴呆患者利培酮随机对照试验数据,采用非线性混合效应模型贝叶斯方法分析药代动力学。年龄显著影响利培酮清除率(β=-1.5),肾小球滤过率影响9-羟基利培酮清除率(β=0.2)。模型预测26.2%(95%CI 18.6-32.6%)的患者活性部分浓度-剂量比超过14 ng/mL per mg/day,支持治疗药物监测必要性。

要点

  • 年龄显著影响利培酮清除率,需根据年龄调整剂量。
  • 26.2%患者活性部分C/D比超过14 ng/mL per mg/day毒性阈值。
  • 治疗初期应进行治疗药物监测以识别毒性高风险患者。

核心结论

  • 年龄相关利培酮剂量调整很重要,治疗初期应进行治疗药物监测以识别毒性高风险患者。

研究设计与样本

  • 基于痴呆患者利培酮随机对照试验数据的非线性混合效应模型分析,采用贝叶斯方法,协变量包括年龄和肾小球滤过率。

主要发现

  • 年龄对利培酮清除率有显著影响(β=-1.5),肾小球滤过率对9-羟基利培酮清除率有显著影响(β=0.2)。
  • 模型预测26.2%(95%CI 18.6-32.6%)的患者活性部分C/D比超过14 ng/mL per mg/day。

关键数值与推荐

  • 活性部分(利培酮和9-羟基利培酮)C/D比高于14 ng/mL per mg/day与锥体外系副作用风险增加相关。

临床怎么用

  • 在痴呆患者初始治疗阶段进行治疗药物监测,识别C/D比超过14 ng/mL per mg/day的高风险患者。
  • 根据年龄调整利培酮剂量以降低毒性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous analysis of pharmacokinetic data on risperidone-treated patients with dementia predicted that 20% had concentration-to-dose (C/D) ratios of the active moiety (risperidone and 9-hydroxy(OH)-risperidone) above 14 ng/mL per mg/day, which were in turn associated with a greater risk of extrapyramidal side effects. This study aimed to further explore risperidone pharmacokinetics in a second dataset. Nonlinear mixed effects modelling, using a Bayesian approach, was applied to data from a randomized controlled trial of risperidone in people with dementia. Covariates included age and glomerular filtration rate (GFR). Age had a significant effect on risperidone clearance (β = -1.5) and GFR on 9-OH-risperidone clearance (β = 0.2). The model predicted that 26.2% (95% confidence interval 18.6-32.6%) had C/D ratios above 14 ng/mL per mg/day. These findings confirm the importance of age-related risperidone dose adjustments and argue strongly for therapeutic drug monitoring in the initial stages of treatment to identify those at greatest risk of toxicity.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Roughley M, Mena C, Howard R, et al. Guiding safer risperidone prescribing in Alzheimer's disease with therapeutic drug monitoring. Br J Clin Pharmacol. 2023. PMID: 36791792. doi:10.1111/bcp.15692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。